Cargando…

Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis

Purulent meningitis (PM) is a severe disease, characterized by high mortality and a formation of a residual neurological deficit. Loss of treatment of PM leads to the lethal outcome in 100% of cases. In addition, death and the development of residual neurological complications are possible despite a...

Descripción completa

Detalles Bibliográficos
Autores principales: Agarkova, Alina, Pokrovskii, Mikhail, Kolesnichenko, Pavel, Gureev, Vladimir, Gudyrev, Oleg, Peresypkina, Anna, Soldatov, Vladislav, Nesterov, Arkadii, Denisyuk, Tatyana, Korokin, Mikhail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998598/
https://www.ncbi.nlm.nih.gov/pubmed/33799578
http://dx.doi.org/10.3390/biomedicines9030285
_version_ 1783670588781363200
author Agarkova, Alina
Pokrovskii, Mikhail
Kolesnichenko, Pavel
Gureev, Vladimir
Gudyrev, Oleg
Peresypkina, Anna
Soldatov, Vladislav
Nesterov, Arkadii
Denisyuk, Tatyana
Korokin, Mikhail
author_facet Agarkova, Alina
Pokrovskii, Mikhail
Kolesnichenko, Pavel
Gureev, Vladimir
Gudyrev, Oleg
Peresypkina, Anna
Soldatov, Vladislav
Nesterov, Arkadii
Denisyuk, Tatyana
Korokin, Mikhail
author_sort Agarkova, Alina
collection PubMed
description Purulent meningitis (PM) is a severe disease, characterized by high mortality and a formation of a residual neurological deficit. Loss of treatment of PM leads to the lethal outcome in 100% of cases. In addition, death and the development of residual neurological complications are possible despite adequate therapy. The aim of the study was to evaluate the cerebroprotective effects of a new pharmacological compound 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid (EMHDPA) on the bacterial purulent meningitis in a model of experimental pneumococcal meningitis. Meningitis was simulated by intrathecal injection of the suspension containing Streptococcus pneumoniae at the concentration of 5 × 10(9) CFU/mL. The cerebroprotective effect was evaluated by survival rates, the severity of neurological deficit, investigatory behaviors, and results of short-term and long-term memory tests. The group administered with EMHDPA showed high survival rates, 80%. Animals treated with the studied compound showed a higher clinical assessment of the rat health status and specific force, and a lesser intensity of neurological deficit compared to the control group (p < 0.05). Locomotor activity of the animals treated with EMHDPA was significantly higher compared to the control group (p < 0.05). There is a decrease in the activity of all estimated indicators of oxidative stress in the group administered with 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid relative to the control group: a decrease in the activity of catalase—17%, superoxide dismutase—34%, malondialdehyde and acetylhydroperoxides—50%, and nitric oxide—85% (p < 0.05). Analysis of the data obtained during the experiment leads to the conclusion about the effectiveness of 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid in the treatment of the experimental PM.
format Online
Article
Text
id pubmed-7998598
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79985982021-03-28 Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis Agarkova, Alina Pokrovskii, Mikhail Kolesnichenko, Pavel Gureev, Vladimir Gudyrev, Oleg Peresypkina, Anna Soldatov, Vladislav Nesterov, Arkadii Denisyuk, Tatyana Korokin, Mikhail Biomedicines Article Purulent meningitis (PM) is a severe disease, characterized by high mortality and a formation of a residual neurological deficit. Loss of treatment of PM leads to the lethal outcome in 100% of cases. In addition, death and the development of residual neurological complications are possible despite adequate therapy. The aim of the study was to evaluate the cerebroprotective effects of a new pharmacological compound 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid (EMHDPA) on the bacterial purulent meningitis in a model of experimental pneumococcal meningitis. Meningitis was simulated by intrathecal injection of the suspension containing Streptococcus pneumoniae at the concentration of 5 × 10(9) CFU/mL. The cerebroprotective effect was evaluated by survival rates, the severity of neurological deficit, investigatory behaviors, and results of short-term and long-term memory tests. The group administered with EMHDPA showed high survival rates, 80%. Animals treated with the studied compound showed a higher clinical assessment of the rat health status and specific force, and a lesser intensity of neurological deficit compared to the control group (p < 0.05). Locomotor activity of the animals treated with EMHDPA was significantly higher compared to the control group (p < 0.05). There is a decrease in the activity of all estimated indicators of oxidative stress in the group administered with 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid relative to the control group: a decrease in the activity of catalase—17%, superoxide dismutase—34%, malondialdehyde and acetylhydroperoxides—50%, and nitric oxide—85% (p < 0.05). Analysis of the data obtained during the experiment leads to the conclusion about the effectiveness of 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid in the treatment of the experimental PM. MDPI 2021-03-11 /pmc/articles/PMC7998598/ /pubmed/33799578 http://dx.doi.org/10.3390/biomedicines9030285 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Agarkova, Alina
Pokrovskii, Mikhail
Kolesnichenko, Pavel
Gureev, Vladimir
Gudyrev, Oleg
Peresypkina, Anna
Soldatov, Vladislav
Nesterov, Arkadii
Denisyuk, Tatyana
Korokin, Mikhail
Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis
title Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis
title_full Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis
title_fullStr Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis
title_full_unstemmed Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis
title_short Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis
title_sort cerebroprotective effects of 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid in the treatment of purulent meningitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998598/
https://www.ncbi.nlm.nih.gov/pubmed/33799578
http://dx.doi.org/10.3390/biomedicines9030285
work_keys_str_mv AT agarkovaalina cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis
AT pokrovskiimikhail cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis
AT kolesnichenkopavel cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis
AT gureevvladimir cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis
AT gudyrevoleg cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis
AT peresypkinaanna cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis
AT soldatovvladislav cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis
AT nesterovarkadii cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis
AT denisyuktatyana cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis
AT korokinmikhail cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis